Practice Management News

A vaccine licensed in China protected healthy adults against hepatitis E virus infection for up to 4.5 years, according to newly published data. 

The U.S. Supreme Court today began hearing oral arguments in King vs. Burwell, a case that will determine whether the Internal Revenue Service may extend tax-credit subsidies for health insurance purchased through federal exchanges established by the Affordable Care Act.

Modern humans share certain genomic structural variants in common with Neanderthal and Denisovan hominids, according to recent findings.

CMS released the 2015 National Impact Assessment of Quality Measures Report, demonstrating that the nation has made significant progress in improving the health care delivery system to achieve better care, smarter spending and healthier people, the agency announced in a blog post.

Increased clinician satisfaction with difficult patient encounters was associated with use of the BREATHE OUT technique, which allows physicians to reflect on their own biases and ‘check in’ with themselves before interacting with a difficult patient, according to a recently published study.

The American Society for Parenteral and Enteral Nutrition, or ASPEN, named David Lim, MD, CM, of the University of Alberta, the recipient of the 2015 Harry M. Vars Award for his research on parenteral nutrition-associated liver disease in infants, according to a press release.

SEATTLE — The mean cost per sustained virologic response at 12 weeks among a cohort of patients with hepatitis C virus infection receiving treatment with Olysio and Sovaldi with or without ribavirin, was approximately $171,000, according to data presented at CROI 2015.

SEATTLE — Deferring treatment for hepatitis C virus infection 1 year or more after diagnosis or until evidence of advanced liver disease may increase liver-related mortality, according to data presented at CROI 2015.

The CMS concluded its first successful end-to-end testing week of the new ICD-10 coding, the agency announced in a blog post.

In the TURQUOISE-1 pilot study, a majority of patients coinfected with hepatitis C virus infection genotype 1 and HIV-1 achieved sustained virologic response after treatment with Viekira Pak plus ribavirin, according to newly published data in JAMA.